SRX5741647 YHS_R_2 SRP193950 bp0 For each sample, TRIzol Reagent (Tiangen Biotech Co., Ltd., Beijing, China) was used to extract RNA following the protocol provided by the manufacturer. After cDNA synthesis, samples were subjected to phosphorylation, A base addition, and end-repair according to library construction protocol. Sequencing adapters were then added to both sizes of the cDNA fragments. After PCR amplification of cDNA fragments, the 150-250 bp targets were cleaned up. We then performed paired-end sequencing on an Illumina HiSeq X Ten platform (Illumina Inc, CA, USA) SRS4677150 R-2 YHS_R_2 RNA-Seq TRANSCRIPTOMIC RANDOM HiSeq X Ten SRX5741648 YHS_R_3 SRP193950 bp0 For each sample, TRIzol Reagent (Tiangen Biotech Co., Ltd., Beijing, China) was used to extract RNA following the protocol provided by the manufacturer. After cDNA synthesis, samples were subjected to phosphorylation, A base addition, and end-repair according to library construction protocol. Sequencing adapters were then added to both sizes of the cDNA fragments. After PCR amplification of cDNA fragments, the 150-250 bp targets were cleaned up. We then performed paired-end sequencing on an Illumina HiSeq X Ten platform (Illumina Inc, CA, USA) SRS4677151 R-3 YHS_R_3 RNA-Seq TRANSCRIPTOMIC RANDOM HiSeq X Ten SRX5741649 YHS_L_3 SRP193950 bp0 For each sample, TRIzol Reagent (Tiangen Biotech Co., Ltd., Beijing, China) was used to extract RNA following the protocol provided by the manufacturer. After cDNA synthesis, samples were subjected to phosphorylation, A base addition, and end-repair according to library construction protocol. Sequencing adapters were then added to both sizes of the cDNA fragments. After PCR amplification of cDNA fragments, the 150-250 bp targets were cleaned up. We then performed paired-end sequencing on an Illumina HiSeq X Ten platform (Illumina Inc, CA, USA) SRS4677152 L-3 YHS_L_3 RNA-Seq TRANSCRIPTOMIC RANDOM HiSeq X Ten SRX5741650 YHS_R_1 SRP193950 bp0 For each sample, TRIzol Reagent (Tiangen Biotech Co., Ltd., Beijing, China) was used to extract RNA following the protocol provided by the manufacturer. After cDNA synthesis, samples were subjected to phosphorylation, A base addition, and end-repair according to library construction protocol. Sequencing adapters were then added to both sizes of the cDNA fragments. After PCR amplification of cDNA fragments, the 150-250 bp targets were cleaned up. We then performed paired-end sequencing on an Illumina HiSeq X Ten platform (Illumina Inc, CA, USA) SRS4677153 R-1 YHS_R_1 RNA-Seq TRANSCRIPTOMIC RANDOM HiSeq X Ten SRX5741651 YHS_L_1 SRP193950 bp0 For each sample, TRIzol Reagent (Tiangen Biotech Co., Ltd., Beijing, China) was used to extract RNA following the protocol provided by the manufacturer. After cDNA synthesis, samples were subjected to phosphorylation, A base addition, and end-repair according to library construction protocol. Sequencing adapters were then added to both sizes of the cDNA fragments. After PCR amplification of cDNA fragments, the 150-250 bp targets were cleaned up. We then performed paired-end sequencing on an Illumina HiSeq X Ten platform (Illumina Inc, CA, USA) SRS4677154 L-1 YHS_L_1 RNA-Seq TRANSCRIPTOMIC RANDOM HiSeq X Ten SRX5741652 YHS_L_2 SRP193950 bp0 For each sample, TRIzol Reagent (Tiangen Biotech Co., Ltd., Beijing, China) was used to extract RNA following the protocol provided by the manufacturer. After cDNA synthesis, samples were subjected to phosphorylation, A base addition, and end-repair according to library construction protocol. Sequencing adapters were then added to both sizes of the cDNA fragments. After PCR amplification of cDNA fragments, the 150-250 bp targets were cleaned up. We then performed paired-end sequencing on an Illumina HiSeq X Ten platform (Illumina Inc, CA, USA) SRS4677155 L-2 YHS_L_2 RNA-Seq TRANSCRIPTOMIC RANDOM HiSeq X Ten